{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"4.2","value":"2.5"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"2.8","value":"1.6"},{"groupId":"OG002","lowerLimit":"2.7","upperLimit":"11.5","value":"5.6"},{"groupId":"OG003","lowerLimit":"4.6","upperLimit":"27.6","value":"9.7"},{"groupId":"OG004","lowerLimit":"1.2","upperLimit":"2.8","value":"1.9"},{"comment":"upper 95% confidence interval was not achieved due to high censoring rate.","groupId":"OG005","lowerLimit":"4.0","upperLimit":"NA","value":"9.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of first study treatment until the date of the first observed radiographically documented progressive disease (PD) or death due to any cause, whichever is earlier. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Gastric-GEJ cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort A.\n\nParticipants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort B.","id":"OG000","title":"Cohort A and B"},{"description":"Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG001","title":"Cohort A1"},{"description":"Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG002","title":"Cohort A2"},{"description":"Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG003","title":"Cohort C"},{"description":"Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG004","title":"Cohort D"},{"description":"Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG005","title":"Cohort E"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received at least one dose of the study drug. Censored participants: Cohort A and B = 3; Cohort A1 = 4; Cohort A2 = 8; Cohort C = 10; Cohort D = 3 and Cohort E = 13. Per Protocol, Cohort A and B participants \\[Gastric-GEJ cancer (Second-Third L)\\] were combined and outcome data was analyzed under a single arm (Cohort A and B).","reportingStatus":"POSTED","timeFrame":"Baseline to PD or Death of Any Cause (Up to 24 Months)","title":"Phase 1a and 1b: Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}